An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?

Hardy and Mummery discuss the recent positive findings in the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis. They argue that the results mark a turning point for the Alzheimer’s field, but that taking anti-amyloid therapies into clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardy, John, Mummery, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Scientific Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115350/
https://www.ncbi.nlm.nih.gov/pubmed/36797987
http://dx.doi.org/10.1093/brain/awad049
_version_ 1785028194408071168
author Hardy, John
Mummery, Catherine
author_facet Hardy, John
Mummery, Catherine
author_sort Hardy, John
collection PubMed
description Hardy and Mummery discuss the recent positive findings in the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis. They argue that the results mark a turning point for the Alzheimer’s field, but that taking anti-amyloid therapies into clinical practice will be challenging.
format Online
Article
Text
id pubmed-10115350
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-101153502023-04-20 An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next? Hardy, John Mummery, Catherine Brain Scientific Commentary Hardy and Mummery discuss the recent positive findings in the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis. They argue that the results mark a turning point for the Alzheimer’s field, but that taking anti-amyloid therapies into clinical practice will be challenging. Oxford University Press 2023-02-17 /pmc/articles/PMC10115350/ /pubmed/36797987 http://dx.doi.org/10.1093/brain/awad049 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Scientific Commentary
Hardy, John
Mummery, Catherine
An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
title An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
title_full An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
title_fullStr An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
title_full_unstemmed An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
title_short An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
title_sort anti-amyloid therapy works for alzheimer’s disease: why has it taken so long and what is next?
topic Scientific Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115350/
https://www.ncbi.nlm.nih.gov/pubmed/36797987
http://dx.doi.org/10.1093/brain/awad049
work_keys_str_mv AT hardyjohn anantiamyloidtherapyworksforalzheimersdiseasewhyhasittakensolongandwhatisnext
AT mummerycatherine anantiamyloidtherapyworksforalzheimersdiseasewhyhasittakensolongandwhatisnext
AT hardyjohn antiamyloidtherapyworksforalzheimersdiseasewhyhasittakensolongandwhatisnext
AT mummerycatherine antiamyloidtherapyworksforalzheimersdiseasewhyhasittakensolongandwhatisnext

Ejemplares similares